# Cellectis S.A.: financial statements, quarterly

CLLS · Nasdaq · CIK 1627281 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/clls.md) · [Financials](/companies/clls/financials.md) · [Filings](/companies/clls/filings.md) · [Insiders](/companies/clls/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/clls/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) |
| --- | --- | ---: | ---: | ---: |
| Operating income | $m | not reported | not reported | [(29.6) d](/filings/0001193125-26-116428.md) |
| Income tax | $m | [0.3](/filings/0000950170-24-050016.md) | [0.1 d](/filings/0000950170-24-050016.md) | [0.0 d](/filings/0001193125-26-116428.md) |
| Net income | $m | [(11.4)](/filings/0000950170-24-050016.md) | [(17.5) d](/filings/0000950170-24-050016.md) | [(41.8) d](/filings/0001193125-26-116428.md) |
| Diluted EPS | $ per share | [(0.20)](/filings/0000950170-24-050016.md) | not reported | not reported |
| Basic EPS | $ per share | [(0.20)](/filings/0000950170-24-050016.md) | not reported | not reported |

- Operating income: ifrs-full:ProfitLossFromOperatingActivities
- Income tax: ifrs-full:IncomeTaxExpenseContinuingOperations
- Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent
- Diluted EPS: ifrs-full:DilutedEarningsLossPerShare
- Basic EPS: ifrs-full:BasicEarningsLossPerShare

## Balance sheet

| Line item | Unit | period not labelled (2016-12-31) | FY2017 (2017-12-31) | FY2018 (2018-12-31) | FY2019 (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [255](/filings/0001193125-20-061833.md) | [256](/filings/0001193125-21-069635.md) | [452](/filings/0001193125-22-064482.md) | [341](/filings/0001193125-22-064482.md) | [241](/filings/0001193125-22-064482.md) | [186](/filings/0001193125-23-070116.md) | [93.2](/filings/0001193125-26-116428.md) | not reported | not reported | [137](/filings/0001193125-26-116428.md) | [143](/filings/0001193125-26-116428.md) | [61.5](/filings/0001193125-26-116428.md) |
| Current assets | $m | [312](/filings/0001193125-19-071189.md) | [323](/filings/0001193125-19-071189.md) | [488](/filings/0001193125-20-061833.md) | [392](/filings/0001193125-21-069635.md) | [315](/filings/0001193125-22-064482.md) | [225](/filings/0001193125-23-070116.md) | [122](/filings/0001193125-23-070116.md) | not reported | not reported | not reported | not reported | not reported |
| Total assets | $m | [331](/filings/0001193125-19-071189.md) | [333](/filings/0001193125-19-071189.md) | [501](/filings/0001193125-20-061833.md) | [467](/filings/0001193125-21-069635.md) | [469](/filings/0001193125-22-064482.md) | [382](/filings/0001193125-23-070116.md) | [261](/filings/0000950170-24-050016.md) | [228](/filings/0000950170-24-050016.md) | [210](/filings/0000950170-24-050016.md) | [334](/filings/0000950170-25-039038.md) | [384](/filings/0001193125-26-116428.md) | [325](/filings/0001193125-26-116428.md) |
| Current liabilities | $m | [56.2](/filings/0001193125-19-071189.md) | [45.5](/filings/0001193125-19-071189.md) | [46.9](/filings/0001193125-20-061833.md) | [62.6](/filings/0001193125-21-069635.md) | [52.0](/filings/0001193125-22-064482.md) | [49.3](/filings/0001193125-23-070116.md) | [48.1](/filings/0000950170-24-050016.md) | [42.0](/filings/0000950170-24-050016.md) | [44.0](/filings/0000950170-24-050016.md) | [155](/filings/0000950170-25-039038.md) | [166](/filings/0001193125-26-116428.md) | [146](/filings/0001193125-26-116428.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [250](/filings/0000950170-25-039038.md) | [253](/filings/0001193125-26-116428.md) | [249](/filings/0001193125-26-116428.md) |
| Shareholders' equity | $m | [273](/filings/0001193125-19-071189.md) | [265](/filings/0001193125-19-071189.md) | [409](/filings/0001193125-20-061833.md) | [315](/filings/0001193125-21-069635.md) | [284](/filings/0001193125-22-064482.md) | [221](/filings/0001193125-23-070116.md) | [118](/filings/0000950170-24-050016.md) | [96.6](/filings/0000950170-24-050016.md) | [76.1](/filings/0000950170-24-050016.md) | [84.7](/filings/0000950170-25-039038.md) | [131](/filings/0001193125-26-116428.md) | [75.9](/filings/0001193125-26-116428.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:EquityAttributableToOwnersOfParent

Shares outstanding: 71,751,201 at 2023-12-31, from the cover of the [20-F filed 2024-04-29](/filings/0000950170-24-050016.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.